Free Trial

MediciNova (MNOV) News Today

→ Executive Order To Wipe Out Your Bank Accounts (From Oasis Gold) (Ad)
Free MNOV Stock Alerts
$1.33
-0.04 (-2.92%)
(As of 04:15 PM ET)
Compare
Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends
June 8 at 1:40 AM | americanbankingnews.com
MediciNova (NASDAQ:MNOV) Now Covered by StockNews.com
June 8 at 1:39 AM | marketbeat.com
MediciNova (NASDAQ:MNOV) Receives New Coverage from Analysts at StockNews.com
StockNews.com assumed coverage on shares of MediciNova in a research note on Saturday. They issued a "hold" rating for the company.
June 5, 2024 | globenewswire.com
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer
June 3, 2024 | globenewswire.com
MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024
June 1, 2024 | americanbankingnews.com
StockNews.com Begins Coverage on MediciNova (NASDAQ:MNOV)
May 30, 2024 | marketbeat.com
Short Interest in MediciNova, Inc. (NASDAQ:MNOV) Decreases By 25.5%
MediciNova, Inc. (NASDAQ:MNOV - Get Free Report) was the target of a significant decline in short interest in May. As of May 15th, there was short interest totalling 158,600 shares, a decline of 25.5% from the April 30th total of 212,900 shares. Approximately 0.3% of the company's stock are short sold. Based on an average daily volume of 35,700 shares, the short-interest ratio is presently 4.4 days.
May 28, 2024 | globenewswire.com
MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions
May 23, 2024 | marketbeat.com
MediciNova (NASDAQ:MNOV) Coverage Initiated by Analysts at StockNews.com
StockNews.com began coverage on MediciNova in a research report on Thursday. They set a "hold" rating on the stock.
May 20, 2024 | stockhouse.com
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer
May 20, 2024 | globenewswire.com
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer
May 14, 2024 | globenewswire.com
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome
May 7, 2024 | finanznachrichten.de
MediciNova, Inc.: MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)
May 7, 2024 | globenewswire.com
MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)
April 30, 2024 | finance.yahoo.com
MediciNova (NASDAQ:MNOV) investors are sitting on a loss of 89% if they invested five years ago
April 27, 2024 | marketbeat.com
MediciNova, Inc. (NASDAQ:MNOV) Short Interest Down 26.0% in April
MediciNova, Inc. (NASDAQ:MNOV - Get Free Report) was the target of a significant decrease in short interest during the month of April. As of April 15th, there was short interest totalling 247,000 shares, a decrease of 26.0% from the March 31st total of 333,600 shares. Based on an average daily volume of 49,400 shares, the days-to-cover ratio is presently 5.0 days. Currently, 0.5% of the shares of the company are sold short.
April 2, 2024 | globenewswire.com
MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)
March 27, 2024 | finanznachrichten.de
MediciNova, Inc.: MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan
March 27, 2024 | msn.com
Pre-market Movers: IBIO, DRCT, NUVB, PAYS, LUXH…
March 27, 2024 | marketwatch.com
MediciNova Gets Patent in Japan for Multiple Sclerosis-Related Treatment
March 27, 2024 | tmcnet.com
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan
March 26, 2024 | globenewswire.com
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan
March 20, 2024 | globenewswire.com
MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society
March 20, 2024 | finance.yahoo.com
Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth
March 12, 2024 | globenewswire.com
MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology
February 29, 2024 | finance.yahoo.com
MNOV: Capital Efficient Model and Large Late-Stage Pipeline Makes MediciNova Stand Out Among Peers…
February 28, 2024 | money.usnews.com
Medicinova Inc
January 17, 2024 | finanznachrichten.de
MediciNova, Inc.: MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China
January 17, 2024 | finance.yahoo.com
MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China
December 21, 2023 | finance.yahoo.com
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology
December 6, 2023 | markets.businessinsider.com
MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe
December 6, 2023 | finance.yahoo.com
MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe
November 27, 2023 | finance.yahoo.com
MNOV: Encouraging Phase 2 Glioblastoma Results Presented at SNO…
November 22, 2023 | finance.yahoo.com
The past five years for MediciNova (NASDAQ:MNOV) investors has not been profitable
November 20, 2023 | msn.com
Why Is Neuro-Oncology-Focused MediciNova Stock Trading Higher Today?
November 19, 2023 | finance.yahoo.com
MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology
October 28, 2023 | benzinga.com
MediciNova's Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria
October 27, 2023 | finance.yahoo.com
MediciNova’s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria
October 12, 2023 | finance.yahoo.com
We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely
October 10, 2023 | finance.yahoo.com
MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada
October 5, 2023 | finanznachrichten.de
MediciNova, Inc.: MediciNova Receives Gene Therapy Milestone Payment
October 4, 2023 | finance.yahoo.com
MediciNova Receives Gene Therapy Milestone Payment
September 29, 2023 | finance.yahoo.com
MNOV: Positive Results for MN-166 in Chlorine Gas-Induced Acute Lung Injury Model…
September 28, 2023 | msn.com
MediciNova gains after nonclinical data for lead asset in lung injury
September 27, 2023 | finance.yahoo.com
MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
August 21, 2023 | finance.yahoo.com
MNOV: Expecting Data for MN-166 in GBM and Chlorine Gas-Induced Lung Injury…
August 17, 2023 | finance.yahoo.com
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology
August 16, 2023 | benzinga.com
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Europe
August 16, 2023 | finance.yahoo.com
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Europe
August 16, 2023 | msn.com
Medicinova (NASDAQ:MNOV) Rises on Key Patent Win in Europe
August 15, 2023 | finance.yahoo.com
MediciNova Receives a New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Sclerosis in Europe
Get MediciNova News Delivered to You Automatically

Sign up to receive the latest news and ratings for MNOV and its competitors with MarketBeat's FREE daily newsletter.

It's time to ween off Chinese lithium! (Ad)

As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promising companies to be watching closely

Learn how this American company is leading the lithium-ion revolution

MNOV Media Mentions By Week

MNOV Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

MNOV
News Sentiment
▼
0.15

0.76
▲
Average
Medical
News Sentiment

MNOV News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

MNOV Articles
This Week
▼
3

1
▲
MNOV Articles
Average Week

Get MediciNova News Delivered to You Automatically

Sign up to receive the latest news and ratings for MNOV and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:MNOV) was last updated on 6/10/2024 by MarketBeat.com Staff

From Our Partners
AI's Next Magnificent Seven
The Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.
The Oxford Club | Sponsored
It's time to ween off Chinese lithium!
As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...
Smallcaps Daily | Sponsored
Top 5 Tech Stocks to Buy for 2024
The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...
Daily Market Alerts | Sponsored
Top 5 AI Stocks to Buy for 2024
The electric vehicle boom is accelerating – and fast.
Market Moving Trends | Sponsored
No Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for Free
Optimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...
Hedgeye | Sponsored
Moonshot Coins for the Current Crypto Run
Did you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum s...
Crypto 101 Media | Sponsored
The Only Energy Play You Should Be Looking At
Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...
Wealthpin Pro | Sponsored
The Most Dangerous Time for 401k Owners
The world's most powerful CEO just issued a grave warning to Americans... "This may be the most dangerous t...
Birch Gold | Sponsored